ARK Genomic Revolution ETF Sees Unusually High Options Volume (BATS:ARKG)

ARK Genomic Revolution ETF (BATS:ARKG) was the recipient of unusually large options trading activity on Thursday. Stock investors acquired 14,158 put options on the company. This represents an increase of 60% compared to the average daily volume of 8,868 put options.

ARK Genomic Revolution ETF Price Performance

ARK Genomic Revolution ETF stock opened at $23.55 on Friday. The business has a 50 day moving average price of $28.95 and a 200 day moving average price of $28.46.

Hedge Funds Weigh In On ARK Genomic Revolution ETF

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Wells Fargo & Company MN lifted its position in ARK Genomic Revolution ETF by 11.2% in the 2nd quarter. Wells Fargo & Company MN now owns 2,752,614 shares of the company’s stock worth $93,837,000 after buying an additional 277,885 shares in the last quarter. BNP Paribas Financial Markets raised its holdings in ARK Genomic Revolution ETF by 112.8% in the 4th quarter. BNP Paribas Financial Markets now owns 1,156,701 shares of the company’s stock worth $37,951,000 after acquiring an additional 613,063 shares during the period. Main Management LLC raised its holdings in ARK Genomic Revolution ETF by 21,336.6% in the 4th quarter. Main Management LLC now owns 681,469 shares of the company’s stock worth $22,359,000 after acquiring an additional 678,290 shares during the period. Goldman Sachs Group Inc. grew its position in ARK Genomic Revolution ETF by 271.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 642,800 shares of the company’s stock worth $21,090,000 after purchasing an additional 469,740 shares during the last quarter. Finally, Royal Bank of Canada grew its position in ARK Genomic Revolution ETF by 7.5% in the 3rd quarter. Royal Bank of Canada now owns 234,507 shares of the company’s stock worth $6,533,000 after purchasing an additional 16,433 shares during the last quarter.

ARK Genomic Revolution ETF Company Profile

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.